Advisory Committee Renewals; Correction, 53430 [2014-21369]
Download as PDF
53430
Federal Register / Vol. 79, No. 174 / Tuesday, September 9, 2014 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2014–21379 Filed 9–8–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Georgia Tuberculosis Outbreak Among
Homeless
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice of award.
The Centers for Disease
Control and Prevention (CDC) located
within the United States Department of
Health and Human Services (HHS)
announces a notice of award to the
Georgia Department of Public Health,
Tuberculosis (TB) Program. This award
will be in the amount of $419,095.00.
The purpose of this award is to halt
the further spread of a drug-resistant
strain of tuberculosis associated with
multiple homeless shelters in Fulton
County, Georgia.
SUMMARY:
It is expected the notice of award
will begin on or about September 3,
2014. The project period will be for one
year.
FOR FURTHER INFORMATION CONTACT: Gail
Burns-Grant, Division of Tuberculosis
Elimination, Field Services and
Evaluation Branch, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE., MS E–10, Atlanta, GA 30333;
phone: 404–639–5344; email: GAB2@
cdc.gov.
SUPPLEMENTARY INFORMATION: Currently,
the state of Georgia is experiencing a
public health emergency in Fulton
County where there has been extensive
transmission of a drug-resistant strain of
tuberculosis (TB) associated with
multiple homeless shelters in the
county. The Georgia Department of
Public Health asked CDC to provide
emergency funding for the immediate
implementation of CDC
recommendations provided as a result
of a May 2014 outbreak investigation to
prevent further transmission of this
drug-resistant strain of tuberculosis and
to prevent further deaths associated
with this outbreak. Project number is
CDC–RFA–PS14–1416.
DATES:
Dated: September 4, 2014.
Ron A. Otten,
Acting Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2014–21455 Filed 9–4–14; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0001]
Advisory Committee Renewals;
Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice entitled ‘‘Advisory Committee
Renewals’’ that appeared in the Federal
Register of August 25, 2014 (79 FR
50658). The document announced the
renewal of certain FDA advisory
committees by the Commissioner of
Food and Drugs. The table in the
document contained several errors. This
document corrects those errors.
SUMMARY:
Lisa
Granger, Office of Policy, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, rm. 3330, Silver Spring,
MD 20993–0002, 301–796–9115.
FOR FURTHER INFORMATION CONTACT:
In the
Federal Register of Monday, August 25,
2014, in FR Doc. 2014–20017, on page
50659 the table is corrected to read:
SUPPLEMENTARY INFORMATION:
Name of committee
Date of expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology .......................................................................
Gastrointestinal Drugs Advisory Committee ............................................................................................................................
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)
Arthritis Advisory Committee ...................................................................................................................................................
Pharmacy Compounding Advisory Committee ........................................................................................................................
Anesthetic and Analgesic Drugs Advisory Committee ............................................................................................................
Blood Products Advisory Committee .......................................................................................................................................
Pulmonary-Allergy Drugs Advisory Committee .......................................................................................................................
Drug Safety and Risk Management Advisory Committee .......................................................................................................
Science Advisory Board to the National Center for Toxicological Research ..........................................................................
Peripheral and Central Nervous System Drugs Advisory Committee ....................................................................................
Psychopharmacologic Drugs Advisory Committee .................................................................................................................
Transmissible and Spongiform Encephalopathies Advisory Committee .................................................................................
Science Board to the Food and Drug Administration .............................................................................................................
Allergenic Products Advisory Committee ................................................................................................................................
Dated: September 3, 2014.
Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
tkelley on DSK3SPTVN1PROD with NOTICES
[Docket No. FDA–2014–N–1049]
Exploring the Expansion of
Conditional Approval to Appropriate
Categories of New Animal Drugs
AGENCY:
Food and Drug Administration,
HHS.
VerDate Mar<15>2010
17:39 Sep 08, 2014
Jkt 232001
Notice.
The Food and Drug
Administration (FDA) is announcing
that it is beginning the exploration
process described in a stated
performance goal in the Animal Drug
User Fee Amendments of 2013 (ADUFA
III) goals letter. Consistent with the
performance goal, the FDA is inviting
comments in regard to the Agency
exploring the use of statutory changes to
expand the use of conditional approval
SUMMARY:
Food and Drug Administration
[FR Doc. 2014–21369 Filed 9–8–14; 8:45 am]
BILLING CODE 4164–01–P
ACTION:
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
January 22, 2016.
March 3, 2016.
March 23, 2016.
April 5, 2016.
April 25, 2016.
May 1, 2016.
May 13, 2016.
May 30, 2016.
May 31, 2016.
June 2, 2016.
June 4, 2016.
June 4, 2016.
June 9, 2016.
June 26, 2016.
July 9, 2016.
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 79, Number 174 (Tuesday, September 9, 2014)]
[Notices]
[Page 53430]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-21369]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0001]
Advisory Committee Renewals; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
entitled ``Advisory Committee Renewals'' that appeared in the Federal
Register of August 25, 2014 (79 FR 50658). The document announced the
renewal of certain FDA advisory committees by the Commissioner of Food
and Drugs. The table in the document contained several errors. This
document corrects those errors.
FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3330,
Silver Spring, MD 20993-0002, 301-796-9115.
SUPPLEMENTARY INFORMATION: In the Federal Register of Monday, August
25, 2014, in FR Doc. 2014-20017, on page 50659 the table is corrected
to read:
------------------------------------------------------------------------
Name of committee Date of expiration
------------------------------------------------------------------------
Advisory Committee for January 22, 2016.
Pharmaceutical Science and Clinical
Pharmacology.
Gastrointestinal Drugs Advisory March 3, 2016.
Committee.
Bone, Reproductive and Urologic March 23, 2016.
Drugs Advisory Committee (formerly
Reproductive Health Drugs Advisory
Committee).
Arthritis Advisory Committee........ April 5, 2016.
Pharmacy Compounding Advisory April 25, 2016.
Committee.
Anesthetic and Analgesic Drugs May 1, 2016.
Advisory Committee.
Blood Products Advisory Committee... May 13, 2016.
Pulmonary-Allergy Drugs Advisory May 30, 2016.
Committee.
Drug Safety and Risk Management May 31, 2016.
Advisory Committee.
Science Advisory Board to the June 2, 2016.
National Center for Toxicological
Research.
Peripheral and Central Nervous June 4, 2016.
System Drugs Advisory Committee.
Psychopharmacologic Drugs Advisory June 4, 2016.
Committee.
Transmissible and Spongiform June 9, 2016.
Encephalopathies Advisory Committee.
Science Board to the Food and Drug June 26, 2016.
Administration.
Allergenic Products Advisory July 9, 2016.
Committee.
------------------------------------------------------------------------
Dated: September 3, 2014.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-21369 Filed 9-8-14; 8:45 am]
BILLING CODE 4164-01-P